证券代码：000813 证券简称：德展健康 公告编号：2025-041 德展大健康股份有限公司 关于回购公司股份比例达到 2%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024- ...

Core Viewpoint - The company, Dezhan Health (000813), has announced a share repurchase plan to enhance shareholder value and reduce registered capital [1] Group 1: Share Repurchase Plan - The board and shareholders' meetings are scheduled for July 1 and July 18, 2024, to approve the share repurchase plan [1] - The company plans to use between 200 million and 300 million yuan of its own funds and bank loans for the repurchase, with a maximum buyback price of 3.59 yuan per share [1] - The repurchased shares will be used for cancellation to reduce the company's registered capital [1] Group 2: Repurchase Progress - As of May 26, 2025, the company has repurchased a total of 43.1994 million shares, accounting for 2.00% of the total share capital [1] - The highest transaction price during the repurchase was 3.29 yuan per share, while the lowest was 2.39 yuan per share [1] - The total amount spent on the repurchase reached 119 million yuan, excluding transaction fees [1]

Core Viewpoint - The announcement details the new judicial freezing of shares held by a major shareholder of Dezheng Health, which may impact investor sentiment but is not expected to affect the company's daily operations [2][4]. Group 1: Shareholder Information - The major shareholder, Meilin Holdings Group, holds 186,038,682 shares, representing 8.59% of the total share capital, with 100% of these shares currently frozen [2][3]. - The total number of shares under judicial freezing and pending freezing amounts to 257,887,347 shares, exceeding the total shares held by Meilin Holdings [2][4]. Group 2: Impact on the Company - Meilin Holdings is not the controlling shareholder or actual controller of the company, and the new share freezing is not expected to impact the company's management or operations [4][19]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required [4][19]. Group 3: Auction Information - A sixth auction of shares held by another major shareholder, Shanghai Yueye Equity Investment Management Partnership, is scheduled, involving 199,199,990 shares, which is 9.20% of the total share capital [10][11]. - The auction is part of a liquidation plan confirmed by the Shanghai Third Intermediate People's Court, and the auction results are uncertain due to the ongoing public notice phase [10][19].

德展大健康股份有限公司 关于持股 5%以上股东所持公司股份 第六次拍卖的提示性公告 证券代码：000813 证券简称：德展健康 公告编号：2025-040 股东上海岳野股权投资管理合伙企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次拍卖是依据上海市第三中级人民法院（以下简称"上海市三中院"） 裁定确认的《清算方案》执行，本次公开拍卖股份为上海岳野股权投资管理合伙 企业（有限合伙）（以下简称"上海岳野"）持有的德展大健康股份有限公司（以 下简称"公司""上市公司"）199,199,990 股无限售流通股（其所持公司股份 总数为 323,800,000 股，其中 124,600,010 股已被拍卖但尚未过户），占其所持 公司股份的 61.52%，占公司总股本的比例为 9.20%，占剔除公司回购专用账户股 份数量后的公司总股本比例为 9.34%1。 10 时止（延时除外）在京东司法拍卖平台（https://paimai.jd.com/308594791） 对上述 199,199 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-039 | | 是否为控股 股东或第一 | 本次轮候冻结 | 占其所持 | 占公司总 | 占剔除公司回购专 | 是否为 | 委托 | 轮候冻结 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 股份数量 | | | 用账户股份数量后 | | | 期限 | 轮候冻结 | | 名称 | 大股东及其 | （股） | 股份比例 | 股本比例 | 的公司总股本比例 | 限售股 | 日期 | （月） | 机关 | | | 一致行动人 | | | | | | | | | | 美林控股 | 否 | 36,274,206 | 19.50% | 1.68% | 1.70% | 否 | 2025- | 36 | 北京市石景山 | | | | | | | | | 05-21 | | 区人民法院 | 注 1：上述公司回购专用账户股份数量为公司最近披露的回购股份数量（即截至 2025 年 5 月 13 日公司回购专用账户中的股份数量），有关回购数量请详见公司于 2025 年 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-038 德展大健康股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现议案被否决的情形； 2、本次股东大会没有涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 1、股东出席的总体情况： 通过现场和网络投票的股东 318 人，代表股份 1,058,146,251 股，占公司有 现场会议召开时间为 2025 年 5 月 20 日下午 14:30 时 网络投票时间为 2025 年 5 月 20 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 20 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为：2025 年 5 月 20 日 9:15－15:00 期间的任意时 间。 2、会议召开地点：新疆维吾尔自治区乌鲁木齐市水磨沟区昆仑东街 789 号 金融大厦 15 层德展健康 ...

新疆天阳律师事务所 关于德展大健康股份有限公司 2024 年年度股东大会 法律意见书 天阳证股字[2025]第 21 号 新疆天阳律师事务所 二○二五年五月 1 T&P 新疆天阳律师事务所 德展健康 2024 年年度股东大会 T&P 新疆天阳律师事务所 德展健康 2024 年年度股东大会 新疆天阳律师事务所 关于德展大健康股份有限公司 2024 年年度股东大会法律意见书 天阳证股字[2025]第 21 号 致：德展大健康股份有限公司 新疆天阳律师事务所（下称本所）接受德展大健康股份有限公司（下称 公司）的委托，委派本所常娜娜律师、尹杰律师出席公司 2024 年年度股东大 会，根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国 证券法》（下称《证券法》）和《德展大健康股份有限公司章程》（下称《公 司章程》），按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对 有关的文件和事实进行核查与验证，并出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的文件材料进行了核查 验证。在进行核查验证过程中，公司已向本所保证，其已提供了本所律师认 为的为出具本法律意见书所必需的材料，所提供的原始材料、副 ...

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]

Group 1 - The establishment of the academician expert workstation at Deyizhi Pharmaceutical Co., Ltd. is approved by the Beijing Association for Science and Technology, marking a significant step in the company's innovation-driven development strategy [1] - The collaboration with Academician Yang Baofeng will focus on drug research and development in various fields, including cardiovascular diseases, tumors, metabolic system diseases, pulmonary hypertension, and neurological disorders [1][2] - Deyizhi Health is actively advancing several innovative drug projects, including neuroprotective agents, antithrombotic drugs, and cannabinoid-related medications [2] Group 2 - The partnership with Academician Yang Baofeng's team is expected to enhance the company's technological capabilities and innovation strategies, leading to the development of competitive new products and processes [2] - The approval of the academician expert workstation is seen as a crucial move to improve the company's research capabilities, attract high-end talent, and promote the transformation of research results [3] - The company aims to strengthen existing innovation platforms, enhance technological innovation capabilities, and accelerate the industrialization of research achievements to drive revenue growth and diversify its business structure [3]